Projects eligible for the collaboration are limited to novel therapeutics for human diseases (small molecules and biologics) and associated enabling technologies. At a minimum, key biological insights and support data must exist, and eligible projects cannot possess contractual encumbrances from other industry partners (by virtue of industry sponsored research agreements or material transfer agreements, or other industry contractual or known intellectual property entanglements).